SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+36.98%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$290M
AUM Growth
+$290M
(+23%)
Cap. Flow
+$29.5M
Cap. Flow
% of AUM
10.15%
Top 10 Holdings %
Top 10 Hldgs %
36.73%
Holding
98
New
24
Increased
37
Reduced
19
Closed
12
Top Buys
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$14.5M |
| 2 |
Nuvalent
NUVL
|
$7.79M |
| 3 |
Terns Pharmaceuticals
TERN
|
$6.98M |
| 4 |
Biogen
BIIB
|
$6.09M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$5.5M |
Top Sells
| 1 |
Veracyte
VCYT
|
$11.1M |
| 2 |
Akero Therapeutics
AKRO
|
$7.01M |
| 3 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$6.26M |
| 4 |
Cogent Biosciences
COGT
|
$4.94M |
| 5 |
Nkarta
NKTX
|
$4.77M |
Sector Composition
| 1 | Healthcare | 96.19% |
| 2 | Technology | 0.09% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
LAVA Therapeutics
LVTX
$41.3M
| $1.53M | 0.44% | 437,762 -173,047 | -28% | -$606K |
|
|
CTIC
52
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $1.53M | 0.44% | 254,361 -729,155 | -74% | -$4.38M |
|
|
CLYM
53
Climb Bio, Inc. Common Stock
CLYM
$151M
| $1.5M | 0.43% | 409,202 +7,114 | +2% | +$26.1K |
|
54
Trevi Therapeutics
TRVI
$883M
| $1.48M | 0.42% | 767,631 -171,634 | -18% | -$331K |
|
|
SGEN
55
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.42M | 0.41% | 11,016 +389 | +4% | +$50K |
|
|
AMYT
56
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $1.41M | 0.4% | 192,995 +4,695 | +2% | +$34.3K |
|
57
Compass Therapeutics
CMPX
$483M
| $1.35M | 0.39% | 268,307 +6,217 | +2% | +$31.3K |
|
58
Astria Therapeutics
ATXS
$349M
| $1.21M | 0.35% | +81,204 | New | +$1.21M |
|
59
Intellia Therapeutics
NTLA
$1.22B
| $1.14M | 0.33% | 32,770 +759 | +2% | +$26.5K |
|
60
Pharvaris
PHVS
$1.39B
| $1.13M | 0.32% | +100,000 | New | +$1.13M |
|
|
JBIO
61
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $1.08M | 0.31% | +36,906 | New | +$1.08M |
|
62
Cue Biopharma
CUE
$60M
| $873K | 0.25% | +306,278 | New | +$873K |
|
63
Altimmune
ALT
$338M
| $831K | 0.24% | 50,546 -49,923 | -50% | -$821K |
|
64
Cytokinetics
CYTK
$4.23B
| $802K | 0.23% | +17,500 | New | +$802K |
|
65
Axsome Therapeutics
AXSM
$6.05B
| $771K | 0.22% | +10,000 | New | +$771K |
|
66
Stereotaxis
STXS
$261M
| $735K | 0.21% | 354,925 +8,694 | +3% | +$18K |
|
67
Codexis
CDXS
$246M
| $674K | 0.19% | 144,737 -700 | -0.5% | -$3.26K |
|
68
Design Therapeutics
DSGN
$315M
| $585K | 0.17% | +57,025 | New | +$585K |
|
69
Immunic
IMUX
$80.9M
| $491K | 0.14% | +350,656 | New | +$491K |
|
70
Compugen
CGEN
$132M
| $478K | 0.14% | +667,443 | New | +$478K |
|
71
MeiraGTx Holdings
MGTX
$587M
| $370K | 0.11% | 56,672 +1,330 | +2% | +$8.67K |
|
72
Wave Life Sciences
WVE
$1.53B
| $350K | 0.1% | +50,000 | New | +$350K |
|
73
Braze
BRZE
$2.93B
| $273K | 0.08% | +10,000 | New | +$273K |
|
74
Praxis Precision Medicines
PRAX
$958M
| $234K | 0.07% | 98,409 -1,591 | -2% | -$3.79K |
|
75
uniQure
QURE
$896M
| $227K | 0.06% | +10,000 | New | +$227K |
|